Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;4(9):825-831.
doi: 10.1002/acr2.11485. Epub 2022 Jul 16.

Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

Affiliations

Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

Melissa L Mannion et al. ACR Open Rheumatol. 2022 Sep.

Abstract

Objective: Inactive disease is the treatment goal for juvenile idiopathic arthritis (JIA), but there are multiple measures for disease activity. The objective was to compare individuals with JIA who meet different definitions for inactive disease.

Methods: Disease activity measures were determined at the 1-year follow-up visit for all patients with JIA enrolled in a North American multicenter registry from 2015 to 2019, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. Patient and disease characteristics between those who met only one composite definition of inactive disease were compared by χ2 for categorical variables and Wilcoxon rank sum for continuous variables. The Spearman correlation coefficient was calculated for simple disease measures.

Results: Among all 2904 patients with JIA enrolled in the CARRA Registry with 1-year visit data, 1984 (68%) had no active joints, 1485 (51%) had a physician global score of 0, 1366 (47%) had a patient/parent global score of 0, 1293 (45%) met the American College of Rheumatology provisional criteria for clinical inactive disease (ACR CID), and 1325 (46%) had a clinical Juvenile Arthritis Disease Activity Score (cJADAS10) of 1 or less. Almost half (47%) did not meet either composite definition of inactive disease, and 38% met both ACR CID and cJADAS10 of 1 or less.

Conclusion: In a multicenter cohort of patients with JIA in North America, a large proportion of patients had inactive disease by single or composite measures after 1 year of observation in the Registry. There was significant overlap between patients who met ACR CID criteria and those who had a cJADAS10 of 1 or less. Additional studies are needed to evaluate the reasons for discordance in inactive disease measures.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Venn diagram of simple disease activity measure overlap: PGA of 0 and Pea of 0. (B) Venn diagram of composite disease activity measure overlap: ACR provisional definition of inactive disease and a cJADAS10 of one or less. ACR, American College of Rheumatology; cJADAS10, clinical Juvenile Arthritis Disease Activity Score; PGA, physician global assessment; pea, patient/parent global assessment of well‐being.

References

    1. Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018;77:819–28. - PubMed
    1. Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol 2015;11:290–300. - PubMed
    1. Wallace CA. Developing standards of care for patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2010;49:1213–4. - PubMed
    1. Shoop‐Worrall SJ, Kearsley‐Fleet L, Thomson W, Verstappen SM, Hyrich KL. How common is remission in juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum 2017;47:331–7. - PMC - PubMed
    1. Klein‐Wieringa IR, Brinkman DM, Ten Cate R, Hissink Muller PC. Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment‐to‐target: is (drug‐free) inactive disease already possible? Curr Opin Rheumatol 2020;32:403–13. - PubMed